Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Key Appointments and Retirements at RenaSci

RenaSci – a Sygnature Group company

As RenaSci moves toward even fuller integration with Sygnature, we’re pleased to announce that from 1st of April 2020, Dr Steve Vickers takes on the role of Deputy Director, RenaSci, and Dr Helen Rowley becomes Vice-President, Neuroscience. Both are widely acknowledged as experienced and highly capable scientific leaders and experts in their respective fields, both within RenaSci and across the broader in vivo / drug discovery scientific community. Steve and Helen will work alongside Executive Director Dr Sharon Cheetham, ensuring RenaSci’s continued success and evolution serving our clients together with the wider Sygnature Group.

At the same time as Steve and Helen’s appointments, Dr Rob Jones is retiring from RenaSci and Professor David Heal is leaving to set up a new consultancy venture. This was envisaged at the time of the acquisition of RenaSci by Sygnature Discovery in September 2018. David and Rob founded RenaSci with Sharon in 2001 and created a company based on their considerable scientific reputation that has been built on over the past 20 years. We would like to take this opportunity to thank David and Rob for their considerable contributions to the success of RenaSci. It has been an exciting journey.

However, it is not goodbye to Rob and David just yet. They will both continue to support RenaSci part-time in the future. Rob will work with us in GLP Operations, and David will be working closely with RenaSci on a consultancy basis.  So, we’re pleased that RenaSci will be able to retain the core values that it was built on.

In addition to this we also have exciting plans in place for further bolstering RenaSci’s senior management team, including for the therapeutic area of Abuse & Dependency testing. An announcement regarding this will be issued soon, so watch this space!

As always, we welcome conversations with our customers and partners so please get in touch if you have any questions or if we can be of any support to your projects. You can reach using any of the contact forms on our website.

Latest News

View All

Sygnature Discovery completes acquisition of SB Drug…

Sygnature Discovery partners the Oncology Development Programme…

Sygnature Discovery deploys Iktos’ AI technology ‘Makya™’

Sygnature Discovery acquires Peak Proteins

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

Areas of interest

Discovery Discipline
Therapeutic Areas
The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.